Melatonin uses in oncology: Breast cancer prevention and reduction of the side effects of chemotherapy and radiation

Emilio J. Sanchez-Barcelo, Maria D. Mediavilla, Carolina Alonso-Gonzalez, Russel J Reiter

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Introduction: The possible oncostatic properties of melatonin on different types of neoplasias have been studied especially in hormone-dependent adenocarcinomas. Despite the promising results of these experimental investigations, the use of melatonin in breast cancer treatment in humans is still uncommon. Areas covered: This article reviews the usefulness of this indoleamine for specific aspects of breast cancer management, particularly in reference to melatonin's antiestrogenic and antioxidant properties: i) treatments oriented to breast cancer prevention, especially when the risk factors are obesity, steroid hormone treatment or chronodisruption by exposure to light at night (LAN); ii) treatment of the side effects associated with chemo-or radiotherapy. Expert opinion: The clinical utility of melatonin depends on the appropriate identification of its actions. Because of its SERM (selective estrogen receptor modulators) and SEEM (selective estrogen enzyme modulators) properties, and its virtual absence of contraindications, melatonin could be an excellent adjuvant with the drugs currently used for breast cancer prevention (antiestrogens and antiaromatases). The antioxidant actions also make melatonin a suitable treatment to reduce oxidative stress associated with chemotherapy, especially with anthracyclines, and radiotherapy

Original languageEnglish (US)
Pages (from-to)819-831
Number of pages13
JournalExpert Opinion on Investigational Drugs
Volume21
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Radiation Effects
Melatonin
Breast Neoplasms
Drug Therapy
Radiotherapy
Antioxidants
Hormones
Selective Estrogen Receptor Modulators
Therapeutics
Estrogen Receptor Modulators
Anthracyclines
Expert Testimony
Estrogens
Adenocarcinoma
Oxidative Stress
Obesity
Steroids
Light
Enzymes
Pharmaceutical Preparations

Keywords

  • Breast cancer
  • Chemo prevention
  • Chemotherapy
  • Melatonin
  • Radiotherapy
  • SEEM
  • SERM

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Melatonin uses in oncology : Breast cancer prevention and reduction of the side effects of chemotherapy and radiation. / Sanchez-Barcelo, Emilio J.; Mediavilla, Maria D.; Alonso-Gonzalez, Carolina; Reiter, Russel J.

In: Expert Opinion on Investigational Drugs, Vol. 21, No. 6, 06.2012, p. 819-831.

Research output: Contribution to journalArticle

Sanchez-Barcelo, Emilio J. ; Mediavilla, Maria D. ; Alonso-Gonzalez, Carolina ; Reiter, Russel J. / Melatonin uses in oncology : Breast cancer prevention and reduction of the side effects of chemotherapy and radiation. In: Expert Opinion on Investigational Drugs. 2012 ; Vol. 21, No. 6. pp. 819-831.
@article{bcb3526529c94f8eb27b2fb3898c06c9,
title = "Melatonin uses in oncology: Breast cancer prevention and reduction of the side effects of chemotherapy and radiation",
abstract = "Introduction: The possible oncostatic properties of melatonin on different types of neoplasias have been studied especially in hormone-dependent adenocarcinomas. Despite the promising results of these experimental investigations, the use of melatonin in breast cancer treatment in humans is still uncommon. Areas covered: This article reviews the usefulness of this indoleamine for specific aspects of breast cancer management, particularly in reference to melatonin's antiestrogenic and antioxidant properties: i) treatments oriented to breast cancer prevention, especially when the risk factors are obesity, steroid hormone treatment or chronodisruption by exposure to light at night (LAN); ii) treatment of the side effects associated with chemo-or radiotherapy. Expert opinion: The clinical utility of melatonin depends on the appropriate identification of its actions. Because of its SERM (selective estrogen receptor modulators) and SEEM (selective estrogen enzyme modulators) properties, and its virtual absence of contraindications, melatonin could be an excellent adjuvant with the drugs currently used for breast cancer prevention (antiestrogens and antiaromatases). The antioxidant actions also make melatonin a suitable treatment to reduce oxidative stress associated with chemotherapy, especially with anthracyclines, and radiotherapy",
keywords = "Breast cancer, Chemo prevention, Chemotherapy, Melatonin, Radiotherapy, SEEM, SERM",
author = "Sanchez-Barcelo, {Emilio J.} and Mediavilla, {Maria D.} and Carolina Alonso-Gonzalez and Reiter, {Russel J}",
year = "2012",
month = "6",
doi = "10.1517/13543784.2012.681045",
language = "English (US)",
volume = "21",
pages = "819--831",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Melatonin uses in oncology

T2 - Breast cancer prevention and reduction of the side effects of chemotherapy and radiation

AU - Sanchez-Barcelo, Emilio J.

AU - Mediavilla, Maria D.

AU - Alonso-Gonzalez, Carolina

AU - Reiter, Russel J

PY - 2012/6

Y1 - 2012/6

N2 - Introduction: The possible oncostatic properties of melatonin on different types of neoplasias have been studied especially in hormone-dependent adenocarcinomas. Despite the promising results of these experimental investigations, the use of melatonin in breast cancer treatment in humans is still uncommon. Areas covered: This article reviews the usefulness of this indoleamine for specific aspects of breast cancer management, particularly in reference to melatonin's antiestrogenic and antioxidant properties: i) treatments oriented to breast cancer prevention, especially when the risk factors are obesity, steroid hormone treatment or chronodisruption by exposure to light at night (LAN); ii) treatment of the side effects associated with chemo-or radiotherapy. Expert opinion: The clinical utility of melatonin depends on the appropriate identification of its actions. Because of its SERM (selective estrogen receptor modulators) and SEEM (selective estrogen enzyme modulators) properties, and its virtual absence of contraindications, melatonin could be an excellent adjuvant with the drugs currently used for breast cancer prevention (antiestrogens and antiaromatases). The antioxidant actions also make melatonin a suitable treatment to reduce oxidative stress associated with chemotherapy, especially with anthracyclines, and radiotherapy

AB - Introduction: The possible oncostatic properties of melatonin on different types of neoplasias have been studied especially in hormone-dependent adenocarcinomas. Despite the promising results of these experimental investigations, the use of melatonin in breast cancer treatment in humans is still uncommon. Areas covered: This article reviews the usefulness of this indoleamine for specific aspects of breast cancer management, particularly in reference to melatonin's antiestrogenic and antioxidant properties: i) treatments oriented to breast cancer prevention, especially when the risk factors are obesity, steroid hormone treatment or chronodisruption by exposure to light at night (LAN); ii) treatment of the side effects associated with chemo-or radiotherapy. Expert opinion: The clinical utility of melatonin depends on the appropriate identification of its actions. Because of its SERM (selective estrogen receptor modulators) and SEEM (selective estrogen enzyme modulators) properties, and its virtual absence of contraindications, melatonin could be an excellent adjuvant with the drugs currently used for breast cancer prevention (antiestrogens and antiaromatases). The antioxidant actions also make melatonin a suitable treatment to reduce oxidative stress associated with chemotherapy, especially with anthracyclines, and radiotherapy

KW - Breast cancer

KW - Chemo prevention

KW - Chemotherapy

KW - Melatonin

KW - Radiotherapy

KW - SEEM

KW - SERM

UR - http://www.scopus.com/inward/record.url?scp=84861068106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861068106&partnerID=8YFLogxK

U2 - 10.1517/13543784.2012.681045

DO - 10.1517/13543784.2012.681045

M3 - Article

C2 - 22500582

AN - SCOPUS:84861068106

VL - 21

SP - 819

EP - 831

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 6

ER -